Spectrophotometric methods for determination of enalapril and timolol in bulk and in drug formulations

Ayad, Magda M.; Shalaby, Abdalla; Abdellatef, Hisham E.; Hosny, Mervat M.
February 2003
Analytical & Bioanalytical Chemistry;Feb2003, Vol. 375 Issue 4, p556
Academic Journal
Two simple and accurate spectrophotometric methods for determination of timolol and enalapril maleate are described. The first method is based on chelate formation with palladium(II) chloride in buffered medium. The second method is based on the formation of the colored complex between palladium(II), eosin, and the two cited drugs using methylcellulose as surfactant to increase the solubility and intensity of the formed complexes. Under optimum conditions the complexes showed maximum absorption at 369.4 nm and 362.8 nm for timolol and enalapril maleate, respectively, in the first method and 552.2 and 550.6 nm for the second method. Apparent molar absorptivities were 1.8×103 and 1.3×103 and Sandell's sensitivities were 5.9×10–4 and 2.7×10–4 for timolol and enalapril maleate in the first method; in the second method molar absorptivities were 2.8×104 and 1.1×104 while Sandell's constants were 9.1×10–3 and 2.3×10–3 for timolol and enalapril maleate. The solutions of the complexes obeyed Beer's law in the concentration ranges 20–200 μg mL–1 and 50–300 μg mL–1 for timolol and enalapril maleate, respectively. In the second method, because the reaction was more sensitive the ranges were reduced to 1.6–16 μg mL–1 for timolol 8–56 μg mL–1 for enalapril maleate. The proposed methods were applied to the determination of the two drugs in their pharmaceutical formulation.


Related Articles

  • Development of Vanadometric System for Spectrophotometric Determination of Timolol in Pure and Dosage Forms. Nnadi, Charles O.; Obonga, Wilfred O.; Ogbonna, John D. N.; Ugwu, Linus O. // Tropical Journal of Pharmaceutical Research;Dec2015, Vol. 14 Issue 12, p2223 

    Purpose: To develop a simple vanadometric spectrophotometric method for the assay of timolol. Methods: The oxidation reactions were performed at optimum conditions of 3 mL 20 % v/v H2SO4, 6.5 % w/v ammonium metavanadate, 40 - 60 °C and 5 min for full colour (blue) development. The proposed...

  • WHAT'S NEW IN DRUGS.  // RN;Jan79, Vol. 42 Issue 1, p49 

    Presents an update on drugs as of January 1979. Health claims of the antiglaucoma Timolol maleate drug; Details on the Dobutamine hydrochloride drug, which stimulates beta receptors in the heart.

  • Bimatoprost/timolol.  // Reactions Weekly;10/6/2012, Issue 1422, p13 

    The article describes the cases of two elderly men who developed massive choroidal detachment (CD) during treatment with topical bimatoprost/ timolol.

  • Timolol Effective for Treating Myopic Regression After LASIK. A, Shojaei; M, Eslani; Y, Vali; M, Mansouri // Review of Ophthalmology;Dec2012, Vol. 19 Issue 12, p65 

    The article discusses the result of the prospective and randomized clinical from Iran which shows the efficacy of timolol in the treatment of myopic regression after Laser-Assisted In Situ Keratomileusis (LASIK).

  • Comparison of the Efficacy of the Fixed-Combination Timolol/Dorzolamide Versus Concomitant Administration of Timolol and Dorzolamide. Bacharach, Jason; Delgado, Maria F.; Iwach, Andrew G. // Journal of Ocular Pharmacology & Therapeutics;Apr2003, Vol. 19 Issue 2, p93 

    The purpose of this study was to compare the efficacy of the fixed-combination solution of timolol 0.5%/dorzolamide 2% with the concomitant administration of its components, timolol 0.5% twice a day and dorzolamide 2% twice a day. Ninety-eight patients adequately controlled with a concomitant...

  • A Six-Week, Parallel, Randomized, Double-Blind Study Comparing the Efficacy and Safety of the 0.5% Timolol/2.0% MK-507 Combination B.I.D. to the Concomitant Administration of 0.5% Timolol B.I.D. and 2.0% MK-507 B.I.D. Chen, Yuh-Fang; Yang, Chang-Hao; Hung, Por T. // Journal of Ocular Pharmacology & Therapeutics;Oct2003, Vol. 19 Issue 5, p417 

    This was a 6-week, parallel, randomized, double-blind study comparing the efficacy and safety of the 0.5% timolol/2.0% MK-507 combination b.i.d. to the concomitant administration of 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d. Patients with ocular hypertension or open-angle glaucoma from 21 to 85...

  • Lumigan Resists Diurnal IOP Dip. Quinn, Christopher J. // Review of Optometry;05/15/2001, Vol. 138 Issue 5, p111 

    Presents the advantages of bimotoprost drug in controlling diurnal intraocular pressure variations. Difference between bimatoprost and timolol; Agents in the prostaglandin analog category; Side effects of the medicine.

  • Brand-name glaucoma offers cost-effective treatment. Guttman, Cheryl; Berlin, Michael S.; Cioffi, George A. // Ophthalmology Times;3/1/2002, Vol. 27 Issue 5, p16 

    Reports on the assurance given to U.S. opthalmologists prescribing a branded timolol hemihydrate, Betimol. Comparison of Betimol with other branded timolol products and generics; Factors in which Betimol is pharmacologically equivalent to timolol maleate; Advantage of prescribing Betimol over...

  • Bimatoprost/timolol.  // Reactions Weekly;12/8/2012, Issue 1431, p11 

    The article describes a case of obscured tachycardia in a 45-year-old man with pulmonary emboli that developed when he received bimatoprost/timolol eye drops for glaucoma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics